
LOBSTECH
Indonesia · Agri & FoodTech · Undetermined

Pleryon Therapeutics
China · Biotech & life sciences · Series A
Compatibility /100
43/100
Medium potentialWhy talk
- Complementary sectors: Agri & FoodTech × Biotech & life sciences — room for a joint offer or co-selling.
- Stage not comparable (Undetermined / Series A).
- Pleryon Therapeutics (China) is a regional neighbour in Asia — a natural first step for cross-border expansion.
Score anatomy
Each segment is what one dimension adds, out of 100.
Score by goal
Dimension by dimension
Needs ↔ offers
5.0 / 10 pts
Pleryon Therapeutics can help LOBSTECH.
- LOBSTECH likely needs funding — Pleryon Therapeutics (China, Series A, $18.6M raised) can offer investor introductions (inferred from public profile).
Market bridge
5.0 / 10 pts
Regional bridge.
- Pleryon Therapeutics (China) is a regional neighbour in Asia — a natural first step for cross-border expansion.
Customer potential
0.5 / 5 pts
No obvious buyer/seller or shared customer base.
No supporting signal in the records.
Sector synergy
25.0 / 50 pts
Complementary sectors.
- Complementary sectors: Agri & FoodTech × Biotech & life sciences — room for a joint offer or co-selling.
Stage complementarity
7.5 / 25 pts
Weak stage signal.
- Stage not comparable (Undetermined / Series A).
How the score works
Each dimension gives a value between 0 and 1, multiplied by its weight; the compatibility is the sum (0–100). Weights for “Peers”: Needs ↔ offers 10, Market bridge 10, Customer potential 5, Sector synergy 50, Stage complementarity 25. Declared needs and offers count fully; when a startup has declared nothing, a few needs/offers are inferred from its public profile (for example, no known traction ⇒ needs customers) and count at half value.
Potential blends compatibility (65%) with the mean global score of both startups (35%): 44/100 — high from 50, medium from 36.